img

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.
Benign Prostatic Hyperplasia (BPH) Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Benign Prostatic Hyperplasia (BPH) Drugs market is projected to reach US$ 4195.1 million in 2034, increasing from US$ 3329.5 million in 2022, with the CAGR of 3.3% during the period of 2024 to 2034. Demand from Hospitals and Drugstores are the major drivers for the industry.
North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Benign Prostatic Hyperplasia (BPH) Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Segment by Type
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others

Segment by Application


Hospitals
Drugstores
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Benign Prostatic Hyperplasia (BPH) Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Benign Prostatic Hyperplasia (BPH) Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Benign Prostatic Hyperplasia (BPH) Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Benign Prostatic Hyperplasia (BPH) Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Benign Prostatic Hyperplasia (BPH) Drugs introduction, etc. Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Benign Prostatic Hyperplasia (BPH) Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Benign Prostatic Hyperplasia (BPH) Drugs Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Overview
1.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Type
1.2.1 Alpha-Blocker
1.2.2 Phosphodiesterase Type-5 Inhibitors
1.2.3 Others
1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type
1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Type (2018-2034)
1.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size Review by Type (2018-2024)
1.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2018-2024)
1.4.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Type (2018-2024)
2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Competition by Company
2.1 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Sales (2018-2024)
2.2 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2018-2024)
2.3 Global Top Players by Benign Prostatic Hyperplasia (BPH) Drugs Price (2018-2024)
2.4 Global Top Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Benign Prostatic Hyperplasia (BPH) Drugs Market Competitive Situation and Trends
2.5.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Benign Prostatic Hyperplasia (BPH) Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
2.8 Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Benign Prostatic Hyperplasia (BPH) Drugs Status and Outlook by Region
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Region
3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2018-2024)
3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Region (2018-2024)
3.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Region
3.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2024-2034)
3.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Region (2024-2034)
3.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Benign Prostatic Hyperplasia (BPH) Drugs by Application
4.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Segment by Application
4.1.1 Hospitals
4.1.2 Drugstores
4.1.3 Others
4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application
4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Overview by Application (2018-2034)
4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size Review by Application (2018-2024)
4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2018-2024)
4.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Breakdown by Application (2018-2024)
5 North America Benign Prostatic Hyperplasia (BPH) Drugs by Country
5.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Country
5.1.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2018-2024)
5.1.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Country (2018-2024)
5.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Country
5.2.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2024-2034)
5.2.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Country (2024-2034)
6 Europe Benign Prostatic Hyperplasia (BPH) Drugs by Country
6.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Country
6.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2018-2024)
6.1.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Country (2018-2024)
6.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Country
6.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2024-2034)
6.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Country (2024-2034)
7 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs by Region
7.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Region (2024-2034)
8 Latin America Benign Prostatic Hyperplasia (BPH) Drugs by Country
8.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Country
8.1.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2018-2024)
8.1.3 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Country (2018-2024)
8.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Country
8.2.1 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2024-2034)
8.2.2 Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Country (2024-2034)
9 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs by Country
9.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Eli Lilly
10.1.1 Eli Lilly Company Information
10.1.2 Eli Lilly Introduction and Business Overview
10.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.1.5 Eli Lilly Recent Development
10.2 GlaxoSmithKline
10.2.1 GlaxoSmithKline Company Information
10.2.2 GlaxoSmithKline Introduction and Business Overview
10.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.2.5 GlaxoSmithKline Recent Development
10.3 Astellas Pharma
10.3.1 Astellas Pharma Company Information
10.3.2 Astellas Pharma Introduction and Business Overview
10.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.3.5 Astellas Pharma Recent Development
10.4 Sanofi
10.4.1 Sanofi Company Information
10.4.2 Sanofi Introduction and Business Overview
10.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.4.5 Sanofi Recent Development
10.5 Pfizer
10.5.1 Pfizer Company Information
10.5.2 Pfizer Introduction and Business Overview
10.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.5.5 Pfizer Recent Development
10.6 Abbott
10.6.1 Abbott Company Information
10.6.2 Abbott Introduction and Business Overview
10.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.6.5 Abbott Recent Development
10.7 Allergan
10.7.1 Allergan Company Information
10.7.2 Allergan Introduction and Business Overview
10.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.7.5 Allergan Recent Development
10.8 TEVA
10.8.1 TEVA Company Information
10.8.2 TEVA Introduction and Business Overview
10.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.8.5 TEVA Recent Development
10.9 Mylan
10.9.1 Mylan Company Information
10.9.2 Mylan Introduction and Business Overview
10.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.9.5 Mylan Recent Development
10.10 Novartis
10.10.1 Novartis Company Information
10.10.2 Novartis Introduction and Business Overview
10.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.10.5 Novartis Recent Development
10.11 Merck
10.11.1 Merck Company Information
10.11.2 Merck Introduction and Business Overview
10.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Revenue and Gross Margin (2018-2024)
10.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Products Offered
10.11.5 Merck Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
11.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
11.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
11.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
11.4.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
11.4.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Alpha-Blocker
Table 2. Major Company of Phosphodiesterase Type-5 Inhibitors
Table 3. Major Company of Others
Table 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2024) & (M Units)
Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type (2018-2024)
Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2024) & (US& Million)
Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share in Value by Type (2018-2024)
Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2018-2024) & (US$/Unit)
Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2024-2034) & (M Units)
Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type (2024-2034)
Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2024-2034) & (US$ Million)
Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type (2024-2034)
Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2024-2034) & (US$/Unit)
Table 15. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2024) & (M Units)
Table 16. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 17. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2018-2024)
Table 18. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 19. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2018-2024)
Table 20. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 21. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2018-2024)
Table 22. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 23. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units) by Type (2018-2024)
Table 24. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2024) & (US$ Million)
Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Company (2018-2024) & (M Units)
Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Company (2018-2024)
Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2018-2024)
Table 29. Global Market Benign Prostatic Hyperplasia (BPH) Drugs Price by Company (2018-2024) & (US$/Unit)
Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 32. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2022)
Table 33. Date of Key Manufacturers Enter into Benign Prostatic Hyperplasia (BPH) Drugs Market
Table 34. Key Manufacturers Benign Prostatic Hyperplasia (BPH) Drugs Product Type
Table 35. Mergers & Acquisitions, Expansion Plans
Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2018-2024) & (M Units)
Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Region (2018-2024)
Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2018-2024) & (US$ Million)
Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Region (2018-2024)
Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2024-2034) & (M Units)
Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Region (2024-2034)
Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2024-2034) & (US$ Million)
Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Region (2024-2034)
Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2034)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 48. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) & (M Units)
Table 49. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application (2018-2024)
Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application (2018-2024)
Table 52. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2018-2024) & (US$/Unit)
Table 53. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2024-2034) & (M Units)
Table 54. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application (2024-2034)
Table 55. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2024-2034) & (US$ Million)
Table 56. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application (2024-2034)
Table 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2024-2034) & (US$/Unit)
Table 58. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) (M Units)
Table 59. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 60. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) (M Units)
Table 61. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 62. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) (M Units)
Table 63. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 64. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) (M Units)
Table 65. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 66. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) (M Units)
Table 67. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2024) & (US$ Million)
Table 68. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2024) & (M Units)
Table 69. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Country (2018-2024)
Table 70. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2024) & (US$ Million)
Table 71. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Country (2018-2024)
Table 72. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2024-2034) & (M Units)
Table 73. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Country (2024-2034)
Table 74. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2024-2034) & (US$ Million)
Table 75. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Country (2024-2034)
Table 76. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2024) & (M Units)
Table 77. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Country (2018-2024)
Table 78. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2024) & (US$ Million)
Table 79. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Country (2018-2024)
Table 80. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2024-2034) & (M Units)
Table 81. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Country (2024-2034)
Table 82. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2024-2034) & (US$ Million)
Table 83. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Country (2024-2034)
Table 84. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2018-2024) & (M Units)
Table 85. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Region (2018-2024)
Table 86. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2018-2024) & (US$ Million)
Table 87. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Region (2018-2024)
Table 88. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2024-2034) & (M Units)
Table 89. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Region (2024-2034)
Table 90. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2024-2034) & (US$ Million)
Table 91. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Region (2024-2034)
Table 92. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2024) & (M Units)
Table 93. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Country (2018-2024)
Table 94. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2024) & (US$ Million)
Table 95. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Country (2018-2024)
Table 96. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2024-2034) & (M Units)
Table 97. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Country (2024-2034)
Table 98. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2024-2034) & (US$ Million)
Table 99. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Country (2024-2034)
Table 100. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2024) & (M Units)
Table 101. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Country (2018-2024)
Table 102. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2018-2024) & (US$ Million)
Table 103. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Country (2018-2024)
Table 104. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2024-2034) & (M Units)
Table 105. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Country (2024-2034)
Table 106. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2024-2034) & (US$ Million)
Table 107. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Country (2024-2034)
Table 108. Eli Lilly Company Information
Table 109. Eli Lilly Introduction and Business Overview
Table 110. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 111. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 112. Eli Lilly Recent Development
Table 113. GlaxoSmithKline Company Information
Table 114. GlaxoSmithKline Introduction and Business Overview
Table 115. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 116. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 117. GlaxoSmithKline Recent Development
Table 118. Astellas Pharma Company Information
Table 119. Astellas Pharma Introduction and Business Overview
Table 120. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 121. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 122. Astellas Pharma Recent Development
Table 123. Sanofi Company Information
Table 124. Sanofi Introduction and Business Overview
Table 125. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 126. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 127. Sanofi Recent Development
Table 128. Pfizer Company Information
Table 129. Pfizer Introduction and Business Overview
Table 130. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 131. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 132. Pfizer Recent Development
Table 133. Abbott Company Information
Table 134. Abbott Introduction and Business Overview
Table 135. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 136. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 137. Abbott Recent Development
Table 138. Allergan Company Information
Table 139. Allergan Introduction and Business Overview
Table 140. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 141. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 142. Allergan Recent Development
Table 143. TEVA Company Information
Table 144. TEVA Introduction and Business Overview
Table 145. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 146. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 147. TEVA Recent Development
Table 148. Mylan Company Information
Table 149. Mylan Introduction and Business Overview
Table 150. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 151. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 152. Mylan Recent Development
Table 153. Novartis Company Information
Table 154. Novartis Introduction and Business Overview
Table 155. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 156. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 157. Novartis Recent Development
Table 158. Merck Company Information
Table 159. Merck Introduction and Business Overview
Table 160. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (Million USD), Price (US$/Unit) and Gross Margin (2018-2024)
Table 161. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product
Table 162. Merck Recent Development
Table 163. Key Raw Materials Lists
Table 164. Raw Materials Key Suppliers Lists
Table 165. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Table 166. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Table 167. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges
Table 168. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Table 169. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List
Table 170. Benign Prostatic Hyperplasia (BPH) Drugs Downstream Customers
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Status and Outlook (2018-2034) & (M Units)
Figure 5. Product Picture of Alpha-Blocker
Figure 6. Global Alpha-Blocker Sales YoY Growth (2018-2034) & (M Units)
Figure 7. Product Picture of Phosphodiesterase Type-5 Inhibitors
Figure 8. Global Phosphodiesterase Type-5 Inhibitors Sales YoY Growth (2018-2034) & (M Units)
Figure 9. Product Picture of Others
Figure 10. Global Others Sales YoY Growth (2018-2034) & (M Units)
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2018-2034) & (US$ Million)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type in 2022 & 2034
Figure 13. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2022
Figure 14. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2022
Figure 15. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2022
Figure 16. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2022
Figure 17. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2022
Figure 18. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2022
Figure 19. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2022
Figure 20. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2022
Figure 21. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Type in 2022
Figure 22. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Type in 2022
Figure 23. The 5 and 10 Largest Manufacturers in the World: Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Sales in 2022
Figure 24. The 5 and 10 Largest Manufacturers in the World: Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2022
Figure 25. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 26. Product Picture of Hospitals
Figure 27. Global Hospitals Sales YoY Growth (2018-2034) & (M Units)
Figure 28. Product Picture of Drugstores
Figure 29. Global Drugstores Sales YoY Growth (2018-2034) & (M Units)
Figure 30. Product Picture of Others
Figure 31. Global Others Sales YoY Growth (2018-2034) & (M Units)
Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2018-2034) & (US$ Million)
Figure 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application in 2022 & 2034
Figure 34. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2022
Figure 35. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2022
Figure 36. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2022
Figure 37. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2022
Figure 38. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2022
Figure 39. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2022
Figure 40. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Volume by Application in 2022
Figure 41. Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2022
Figure 42. Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share in Value by Application in 2022
Figure 43. Key Raw Materials Price
Figure 44. Benign Prostatic Hyperplasia (BPH) Drugs Manufacturing Cost Structure
Figure 45. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain Analysis
Figure 46. Channels of Distribution
Figure 47. Distributors Profiles
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries